Search results for " sarcoma"

showing 10 items of 180 documents

Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression.

2014

ABSTRACT Background At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of patients according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma (EWS) patients. This study aimed to explore the role of miR-34A expression on prognosis of EWS patients. Patients and methods Specimens from 109 patients with non-metastatic EWS treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, EW-1, EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 metastases were studied. Sixty-eight patients (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9–241 months). Ex…

AdultMalePrognosiHydro-Lyasemedicine.medical_treatmentSarcoma EwingDisease-Free SurvivalCyclin D1medicineHumansCyclin D1Neoplasm Metastasisprognostic biomarkerNeoadjuvant therapyHydro-LyasesAged 80 and overTissue microarraybiologybusiness.industryProportional hazards modelMedicine (all)Ewing's sarcomaMicroRNAHematologyMiddle Agedmedicine.diseasePrognosisNeoadjuvant TherapyNeoplasm MetastasiGene Expression Regulation NeoplasticMicroRNAsKi-67 AntigenTreatment OutcomeOncologyDrug Resistance NeoplasmKi-67biology.proteinCancer researchKi-67ImmunohistochemistryFemaleSarcomacyclin D1; Ewing sarcoma; Ki-67; miR-34a; prognostic biomarkers; Adult; Aged 80 and over; Cyclin D1; Disease-Free Survival; Drug Resistance Neoplasm; Female; Gene Expression Regulation Neoplastic; Humans; Hydro-Lyases; Ki-67 Antigen; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Sarcoma Ewing; Treatment Outcome; Medicine (all)businessEwing sarcomamiR-34aHumanAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Patients with soft tissue sarcoma comprise a higher probability of comorbidities than cancer-free individuals. A secondary data analysis.

2016

Soft tissue sarcoma comprises a heterogeneous group of solid malignant tumours. Comorbidities are important prognostic factors for survival and adversely impact quality of life. We examined the complex relationship between soft tissue sarcoma and comorbidities over time in a large population-based sample. The study uses routine data from the German statutory healthcare system (n = 2,615,865). Case identification of soft tissue sarcoma and comorbid diseases was based on ICD-10 codes and diagnostic modifiers. Uni- and multivariate regression models were used to obtain risk estimates for chronic somatic and mental comorbidities in soft tissue sarcoma patients compared to a cancer-free control …

AdultMalemedicine.medical_specialtyAdolescentAdjustment disordersSoft Tissue NeoplasmsComorbidityAngina03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsInternal medicineGermanymedicinePrevalenceHumans030212 general & internal medicineRisk factorChildDepression (differential diagnoses)AgedAged 80 and overbusiness.industrySoft tissue sarcomaInfantSarcomaMiddle Agedmedicine.diseaseComorbiditySurgeryOncology030220 oncology & carcinogenesisChild PreschoolRegression AnalysisFemaleSarcomabusinessAnxiety disorderEuropean journal of cancer care
researchProduct

Risk Factors for Classical Kaposi Sarcoma in a Population-based Case-control Study in Sicily

2008

Abstract Background: Classical Kaposi sarcoma is a rare complication of Kaposi sarcoma-associated herpes virus (KSHV) infection. We conducted a population-based, frequency-matched case-control study in Sicily to further investigate the reported inverse relationship between smoking and classical Kaposi sarcoma and to identify other factors associated with altered risk. Methods: All incident, histologically confirmed classical Kaposi sarcoma cases in Sicily were eligible. A two-stage cluster sample design was applied to select population controls. KSHV seropositivity was determined using four antibody assays (K8.1 and orf73 enzyme immunoassays and two immunofluorenscence assays). Using SAS-ca…

AdultMalemedicine.medical_specialtyEpidemiologyPopulationSettore MED/42 - Igiene Generale E ApplicataArticleRisk FactorsInternal medicinemedicineCKS risk factors SicilyHumanseducationSarcoma KaposiSicilyAgedAged 80 and overeducation.field_of_studyChi-Square DistributionClassic Kaposi Sarcomabusiness.industryIncidenceIncidence (epidemiology)SmokingCase-control studyvirus diseasesCancerOdds ratioMiddle Agedmedicine.disease/dk/atira/pure/subjectarea/asjc/2700/2730Logistic ModelsOncologyCase-Control Studies/dk/atira/pure/subjectarea/asjc/2700/2713ImmunologyFemaleSarcomabusinessChi-squared distribution
researchProduct

Systemic Treatment in Advanced Phyllodes Tumor of the Breast: A Multi-institutional European Retrospective Case-series Analyses

2022

Abstract Background: We aimed at investigating outcome of systemic treatments in advanced breast PT. Methods: All cases of advanced breast PT treated with systemic treatments from 1999 to 2019, in one of the referral sarcoma centres involved in the study, were retrospectively reviewed. Results: 56 female patients were identified. Median age was 52 (range 25-76) years. Patients re-ceived a median number of 2 systemic treatments (range 1-4). Best responses according to RECIST were: 1 (3.7%) CR, 11 (40.7%) PR, 6 (22.2%) SD, 9 (33.3%) PD with anthracyclines plus ifosfamide (AI); 2 (16.7%) PR, 4 (33.3%) SD, 6 (50.0%) PD with anthracycline alone; 3 (18.8%) PR, 4 (25.0%) SD, 9 (56.3%) PD with high…

AdultOncologyCancer Researchmedicine.medical_specialtyAdvanced setting; Breast tumor; Chemotherapy; Phyllodes; SarcomaBreast tumorBreast NeoplasmsAdvanced settingInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineChemotherapyResponse Evaluation Criteria in Solid TumorsAgedRetrospective StudiesSeries (stratigraphy)business.industryPhyllodes tumorPhyllodesSarcomaMiddle Agedmedicine.diseaseOncologyFemalebusiness
researchProduct

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgeme…

2007

Abstract Objective. A multicenter non-randomized phase II study was initiated to evaluate tolerability and efficacy of pegylated liposomal doxorubicin (PLD) in combination with carboplatin in gynecologic malignancies. Methods. One hundred forty women with recurrent or advanced endometrial ( n =31), cervical or vaginal cancer ( n =31), uterine sarcomas ( n =11), or recurrent platinum-sensitive ovarian cancer ( n =67) received six courses of PLD 40 mg/m 2 and carboplatin (AUC 6) every 28 days. Results. Hematological toxicities with NCI-CTC grade 3/4 were anemia in 8%, thrombocytopenia in 14%, neutropenia in 24%, and febrile neutropenia in 2% of 652 cycles. Grade 3/4 non-hematological toxiciti…

AdultOncologymedicine.medical_specialtyGenital Neoplasms FemalePhases of clinical researchNeutropeniaGastroenterologyDrug Administration ScheduleCarboplatinPolyethylene Glycolschemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesInfusions IntravenousAgedAged 80 and overVaginal cancerUterine sarcomabusiness.industryEndometrial cancerObstetrics and GynecologyMiddle Agedmedicine.diseaseCarboplatinOncologychemistryDoxorubicinFemaleOvarian cancerbusinessFebrile neutropeniaGynecologic Oncology
researchProduct

Cytoskeletal Heterogeneity of an Epithelioid Sarcoma with Expression of Vimentin, Cytokeratins, and Neurofilaments

1990

We studied an unusual sarcoma with morphologic features diagnostic of epithelioid sarcoma by conventional light microscopy, transmission electron microscopy, and immunohistochemistry. The primary tumor, which was located in the deep soft tissues of the buttock of a 32-year-old woman, and its metastases to lymph nodes, liver, and lung were available for investigation. The histomorphological and ultrastructural appearance of the primary tumor and its metastatic deposits were typical of epithelioid sarcoma. Immunohistochemistry revealed a strong and uniform reactivity for vimentin in both the primary tumor and its metastases. In contrast, a marked cytoskeletal heterogeneity became evident for …

AdultPathologymedicine.medical_specialtyLung NeoplasmsNeurofilamentEpithelioid sarcomaIntermediate FilamentsVimentinBiologyEndoplasmic ReticulumPathology and Forensic MedicinemedicineHumansVimentinIntermediate filamentCytoskeletonLiver NeoplasmsSarcomamedicine.diseaseImmunohistochemistryPrimary tumorMicroscopy ElectronLymphatic Metastasisbiology.proteinButtocksKeratinsImmunohistochemistryFemaleSurgeryLymph NodesSarcomaLymphAnatomyThe American Journal of Surgical Pathology
researchProduct

Imaging findings of primary breast sarcoma : results of a first multicenter study

2016

Abstract Purpose To investigate imaging findings in patients with primary breast sarcoma (PBS). Materials and methods A retrospective search in the databases of 10 radiological departments in Germany from 2000 to 2011 was performed. Only histologically proven cases of PBS were included into the study. Mammography was available in 31 patients (33 lesions), ultrasound images in 24 patients (24 lesions), and for 10 patients (14 lesions) magnetic resonance imaging (MRI) of the breast was performed. The breast findings were classified according to the American College of Radiology Breast Imaging Reporting and Data Systems (BI-RADS) 5th edition categories. Collected data were evaluated by means o…

Adultmedicine.medical_specialtyBreast SarcomaBreast imagingMedizinBI-RADSBreast Neoplasms030218 nuclear medicine & medical imagingDiagnosis Differential03 medical and health sciences0302 clinical medicinemedicineMammographyHumansRadiology Nuclear Medicine and imagingBreastAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryUltrasoundMagnetic resonance imagingSarcomaGeneral MedicineMiddle AgedAcoustic shadowMagnetic Resonance Imaging3. Good health030220 oncology & carcinogenesisFemaleRadiologyUltrasonography MammaryDifferential diagnosisbusinessMammography
researchProduct

Dermoscopic characteristics of a cutaneous histiocytic sarcoma in a young patient

2017

Adultmedicine.medical_specialtySkin Neoplasmsbusiness.industryJuvenile xanthogranulomaBreast NeoplasmsDermoscopyDermatologyHistiocytic sarcomamedicine.diseaseDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisHumansMedicineFemaleHistiocytic SarcomabusinessHistiocyteJournal of the American Academy of Dermatology
researchProduct

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

2011

Background\ud Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating osteoclasts formation and activity. RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG.\ud \ud Materials and Methods\ud We examined mRNA expression levels of RANKL/RANK/OPG in a publicly available microarray dataset of 295 primary breast cancer patients. We next analyzed RANK expression by immunohistochemistry in an independent series of 93 primary breast cancer specimens and investigated a possible association with clinicopathological parameters, bone recurrence and surviv…

Anatomy and PhysiologyMicroarraysSettore MED/06 - Oncologia MedicaCancer TreatmentLigandsMetastasisBone remodelingMetastasisBasic Cancer ResearchBreast TumorsBone and Soft Tissue SarcomasNeoplasm MetastasisMusculoskeletal SystemOligonucleotide Array Sequence AnalysisMultidisciplinaryPredictive markerReceptor Activator of Nuclear Factor-kappa BQRBone metastasisMiddle AgedImmunohistochemistryGene Expression Regulation NeoplasticOncologyRANKLMedicineFemaleResearch Articlemusculoskeletal diseasesmedicine.medical_specialtyHistologyScienceBone NeoplasmsBreast NeoplasmsBiologyBreast cancerAntibody TherapySDG 3 - Good Health and Well-beingOsteoprotegerinInternal medicinemedicineHumansRNA MessengerBoneBiologyAgedBreast cancer bone metastasis RANK-RANKLRANK LigandOsteoprotegerinComputational BiologyCancers and NeoplasmsRANK Ligandmedicine.diseaseEndocrinologyCancer researchbiology.protein
researchProduct

Computed tomography bone density variations in oncological patients undergoing antiresorptive medication

2021

The purpose of this study was to compare jaw and cervical vertebrae bone density in computed tomography (CT) analyses of oncological patients undergoing antiresorptive medication with control patients, aiming to find information that may assist the radiologist and clinician in predicting risks and monitoring osteonecrosis in the jaw. Thirty-one patients treated with zoledronic acid and 37 control were included in the study. Two areas in regions of interest were chosen and standardized, one in the lower portion of the mandible and another in the axial cervical vertebra (C2) of patients undergoing antiresorptive drug treatment (experimental group) and the control group. Density analysis was p…

Bone Density Conservation AgentsDiphosphonatesReproducibility of Resultsmyofibromadesmoplastic fibromaOtorhinolaryngologynodular fasciitisBone DensityHumansmyofibroblastic sarcomaBisphosphonate-Associated Osteonecrosis of the JawSurgeryinflammatory myofibroblastic tumorTomography X-Ray ComputedGeneral DentistryUNESCO:CIENCIAS MÉDICAS
researchProduct